study | M/F | Tumor stage | Marker | Location | Number(H/L) | Cutoff | Outcome |
---|---|---|---|---|---|---|---|
Wartenberg M 201 5[22] | 120(64/53) | 3/98/4/10 (I/II/III/IV) | FoxP3+ | I | 53/55 | Median normalized value | OS |
 |  |  |  | P | 50/58 | Median normalized value | OS |
Tang Y 201 4[23] | 45(28/17) | 34/11 (I+II/III+IV) | CD4+CD25+Foxp3+ | I | 22/23 | Median value | OS |
Wang X 201 5[24] | 120(66/54) | 28/92 (I+II/III+IV) | FoxP3+ | I | 76/44 | Not mentioned | OS |
 |  |  |  |  |  |  | PFS |
Ino Y 201 3[4] | 212(132/80) | 2/188/0/22 (I/II/III/IV) | FoxP3+ CD4+ | Â | 106/64 | Not mentioned | OS |
 |  |  |  |  |  |  | PFS |
Liu L 201 6[25] | 92(68/24) | 25/41/26 (I/II/III) | FoxP3+ | I | 44/48 | Median value | OS |
 |  |  |  |  |  |  | PFS |
 |  |  |  | P | 36/56 | Median value | OS |
 |  |  |  |  |  |  | PFS |
Hiraoka N 200 6[26] | 198(114/84) | 16/10/74/98 (I/II/III/IV) | FoxP3+ | I | 104/94 | Not mentioned | OS |
Diana A 201 6[27] | 145(77/68) | 88/57 (I+II/III+IV) | FoxP3+ | I | 38/107 | Not mentioned | OS |
 |  |  |  | I |  |  | DFS |
Zhang K 201 5[28] | 40(26/14) | 4/16/0/6 (I/II/III/IV) | FoxP3+ | I | 24/16 | Not mentioned | OS |